These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26577284)

  • 1. Antibody-Drug Conjugates.
    Peng L; Chen X
    Bioconjug Chem; 2015 Nov; 26(11):2169. PubMed ID: 26577284
    [No Abstract]   [Full Text] [Related]  

  • 2. Noninternalizing targeted cytotoxics for cancer therapy.
    Casi G; Neri D
    Mol Pharm; 2015 Jun; 12(6):1880-4. PubMed ID: 25738312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins.
    Merten H; Brandl F; Plückthun A; Zangemeister-Wittke U
    Bioconjug Chem; 2015 Nov; 26(11):2176-85. PubMed ID: 26086208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Drug Conjugates for Cancer Therapy.
    Polakis P
    Pharmacol Rev; 2016 Jan; 68(1):3-19. PubMed ID: 26589413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
    Malik P; Phipps C; Edginton A; Blay J
    Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody conjugates and therapeutic strategies.
    McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
    Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates- stability and formulation.
    Duerr C; Friess W
    Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody drug conjugates: lessons from 20 years of clinical experience.
    Tolcher AW
    Ann Oncol; 2016 Dec; 27(12):2168-2172. PubMed ID: 27733376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy.
    Maruani A; Smith ME; Miranda E; Chester KA; Chudasama V; Caddick S
    Nat Commun; 2015 Mar; 6():6645. PubMed ID: 25824906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
    Brumlik MJ; Daniel BJ; Waehler R; Curiel DT; Giles FJ; Curiel TJ
    Expert Opin Drug Deliv; 2008 Jan; 5(1):87-103. PubMed ID: 18095930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunoconjugates, drug-armed antibodies to fight against cancer].
    Haeuw JF; Caussanel V; Beck A
    Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How antibody-drug conjugates aim to take down cancer.
    Plackett B
    Nature; 2024 May; 629(8014):S2-S3. PubMed ID: 38811702
    [No Abstract]   [Full Text] [Related]  

  • 13. Maturing antibody-drug conjugate pipeline hits 30.
    Mullard A
    Nat Rev Drug Discov; 2013 May; 12(5):329-32. PubMed ID: 23629491
    [No Abstract]   [Full Text] [Related]  

  • 14. Naptumomab estafenatox: a new immunoconjugate.
    Robinson MK; Alpaugh RK; Borghaei H
    Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models.
    Chen Q; Millar HJ; McCabe FL; Manning CD; Steeves R; Lai K; Kellogg B; Lutz RJ; Trikha M; Nakada MT; Anderson GM
    Clin Cancer Res; 2007 Jun; 13(12):3689-95. PubMed ID: 17575234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.
    Drachman JG; Senter PD
    Hematology Am Soc Hematol Educ Program; 2013; 2013():306-10. PubMed ID: 24319196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
    Hasan M; Alam S; Poddar SK
    Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the development and manufacturing of antibody-drug conjugates.
    Ducry L
    Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.
    Yin H; Meng T; Shu L; Mao M; Zhou L; Chen H; Song D
    Chem Biol Drug Des; 2017 Nov; 90(5):892-899. PubMed ID: 28440948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.